Vetoquinol (VETO.PA)

Executive Summary

Vetoquinol is a global animal health company based in France, with 2023 consolidated sales of €545 million. The company specializes in veterinary pharmaceuticals and medicinal feed additives for both livestock and companion animals, operating in over 100 countries. As an independent, vertically integrated player, Vetoquinol differentiates itself through applied R&D and innovative formulation technologies, which have supported a portfolio of 10 commercial products and a steady pipeline. The company is publicly traded on Euronext Paris (VETO.PA) with a market capitalization of approximately €872 million. Despite a challenging macroeconomic environment, Vetoquinol has maintained resilient performance, driven by its diversified geographic footprint and balanced exposure between production animals and companion animals. The company's focus on high-growth regions and ongoing investment in R&D position it for sustained long-term growth. Key priorities include leveraging its proprietary formulation platforms to launch new products, expanding market access in emerging economies, and pursuing selective bolt-on acquisitions to enhance its product portfolio. With a solid balance sheet and a track record of consistent profitability, Vetoquinol is well-equipped to capitalize on the growing demand for animal health products, particularly in the companion animal segment, which offers higher margins and growth rates.

Upcoming Catalysts (preview)

• Q2 2026Launch of innovative companion animal products in large markets (e.g., US, EU)70% success
• Q4 2026Expansion in Asian markets through new partnerships or direct distribution agreements60% success
• TBDStrategic acquisition of a complementary veterinary product line or company50% success